In their study, authors demonstrated that NK cells genetically modified through electroporation with mRNA coding for CD16 158 V/V genotype potentiated NK cells cytotoxicity against lymphoma cells coated with rituximab (187). This evidence concerns the gene FCGR3A and lymphoma.